Targeting rubella for elimination

Area of Science:

• Public Health
• Virology
• Immunization

Background:

• Rubella infection in early pregnancy causes Congenital Rubella Syndrome (CRS) in up to 90% of cases, leading to fetal defects, wastage, stillbirths, and sensorineural hearing loss.
• The RA 27/3 rubella vaccine is highly effective, achieving rubella and CRS elimination in several regions.
• Studies in India indicate rubella seronegativity rates of 10-36% among adolescent girls, posing a risk for pregnant women.

Purpose of the Study:

• To review the effectiveness of rubella vaccination and assess the need for rubella elimination in India.
• To recommend strategies for integrating rubella vaccination into existing immunization programs to prevent Congenital Rubella Syndrome.

Main Methods:

• Review of studies on rubella vaccine (RA 27/3) effectiveness and duration of protection.
• Analysis of seronegativity rates in Indian adolescent girls.
• Evaluation of current measles control strategies in India.

Main Results:

• Rubella vaccination (RA 27/3) provides protection for 10-21 years in over 95% of cases.
• Despite low rubella incidence in India, the introduction of RCV in some areas may lead to suboptimal coverage and increased risk of rubella during pregnancy.
• Synergizing rubella elimination efforts with measles campaigns is a viable strategy.

Conclusions:

• Eliminating rubella and CRS in India is imperative, especially given the risks associated with potential suboptimal vaccine coverage.
• Replacing measles vaccine with MR or MMR vaccine in measles campaigns and routine immunization schedules is recommended for rubella elimination.
• A phased approach integrating rubella vaccination into national immunization strategies can achieve elimination over 10-20 years.